Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [18F]MNI-1126 for Synaptic Density Loss
NCT03587649Phase 1Completed
- Sponsor
- Invicro
- Start
- May 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-SynVesT-1, sponsored by Invicro. Primary endpoint: Regional tracer uptake in VOI template at 1 year. Started May 2018; status: completed.
02
Drugs
18F-SynVesT-1
Beyond the preview
Go deeper on NCT03587649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587649.